Medicare Part D coverage · aspirin · RxCUI 994239
aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
Per the CMS 2026 Part D formulary file, aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] is covered by 129 Medicare Part D plans (2.6% of enrollable products), averaging Tier 2.7, with prior authorization required on 33.3% of covering formularies.
- 2.6%
- Plan coverage
- 129
- Plans covering
- T2.7
- Avg tier
- 33.3%
- Prior auth required
What the CMS Formulary Data Shows for aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
Per the CMS 2026 Part D formulary file, aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] (RxNorm concept RXCUI 994239, generic name aspirin) appears on 15 distinct formulary files spanning 129 Medicare Part D plan offerings - 2.6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.7.
Real-world access to aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] depends on utilization management as much as tier placement: 33.3% of covering formularies require prior authorization. 0% require step therapy. 60% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 22,634 Part D beneficiaries filled aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] in 2023, with total plan-and-beneficiary spending of $31,146,709 and an average per-beneficiary annual cost of $1,376.10. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] today.
Coverage Details
- Formularies covering
- 15
- Plans covering
- 129
- Coverage rate
- 2.6%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 33.3% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 60% of formularies
2023 Medicare Spending
- Beneficiaries
- 22,634
- Total spending
- $31,146,709
- Avg per beneficiary
- $1,376.10
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| PHP (HMO C-snp) | Aids Healthcare Foundation | T1 | Yes | $0 | CA |
| VNS Health Total (HMO D-SNP) | VNS Choice | T1 | No | $0 | NY |
| Gold Dialysis & Kidney Complete (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T1 | No | $4.80 | FL |
| Gold Dialysis & Kidney Complete (HMO-POS C-SNP) | Gold Kidney OF Arizona | T1 | No | $17.00 | AZ |
| VNS Health EasyCare Plus (HMO D-SNP) | VNS Choice | T1 | No | $51.60 | NY |
| Healthy Mississippi Premier Advantage (HMO-POS) | Healthy Mississippi, Inc. | T2 | No | $0 | MS |
| Gold Heart & Diabetes (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Heart & Diabetes Complete (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Health (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T2 | No | $0 | FL |
| Gold Heart & Diabetes (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| Gold Heart & Diabetes (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| Gold Dialysis & Kidney (HMO-POS C-SNP) | Gold Kidney OF Arizona | T2 | No | $0 | AZ |
| VillageCareMAX Medicare Health Advantage Plan (HMO D-SNP) | Village Senior Services Corporation | T2 | Yes | $0 | NY |
| VillageCareMAX Medicare Total Advantage Plan (HMO D-SNP) | Village Senior Services Corporation | T2 | Yes | $0 | NY |
| CareOregon Advantage Plus (HMO D-SNP) | Health Plan OF Careoregon, Inc. | T2 | No | $0 | OR |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | UT |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T3 | No | $0 | NV |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] covered by Medicare Part D?
Yes, aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] is covered by 129 Medicare Part D plans (2.6% of all Part D formularies).
What tier is aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] on Medicare Part D plans?
aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] averages Tier 2.7 across Part D plans, ranging from Tier 1 to Tier 4.
Does aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] require prior authorization?
33.3% of Part D formularies require prior authorization for aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]. Step therapy: 0%. Quantity limits: 60%.
How much does Medicare spend on aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]?
In 2023, total Medicare Part D spending on aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] was $31,146,709, covering 22,634 beneficiaries. The average spend per beneficiary was $1,376.10.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- abacavir 300 MG Oral Tablet T2.7
- escitalopram 1 MG/ML Oral Solution T2.7
- riluzole 50 MG Oral Tablet T2.7
- 168 HR clonidine 0.00417 MG/HR Transdermal System T2.7
- sodium zirconium cyclosilicate 5000 MG Powder for Oral Suspension [Lokelma] T2.7
- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection T2.7
Similar prior-authorization rate
- pretomanid 200 MG Oral Tablet 33.3% PA
- meperidine hydrochloride 50 MG Oral Tablet 33.3% PA
- chlordiazepoxide hydrochloride 5 MG / clidinium bromide 2.5 MG Oral Capsule 33.3% PA
- sevelamer carbonate 800 MG Oral Tablet 33.3% PA
- promethazine hydrochloride 25 MG Rectal Suppository 33.3% PA
- lumateperone 42 MG Oral Capsule [Caplyta] 33.2% PA